class 4 caution in use- Zinacef Vials (all strengths)

Sandoz has detected that information on the diluents in the Patient Information Leaflet (PIL) and Summary of Product Characteristics (SmPC) of cefuroxime contain incorrect information.

MHRA drug alert date: 23rd October 2023

MHRA drug alert link: https://www.gov.uk/drug-device-alerts/class-4-medicines-defect-information-sandoz-limited-zinacef-powder-for-solution-for-injection-or-infusion-vials-all-strengths-including-stock-in-gsk-livery-el-23-a-slash-38?utm_medium=email&utm_campaign=govuk-notifications-topic&utm_source=deab3b91-5e05-461a-94d7-cc812d40c9b7&utm_content=immediately

This is a caution in use only we are not accepting stock returns

Further Information

For more information, medical information queries, please contact: sandozgb@EU.propharmagroup.com, Telephone: +44 1276 698 101. For stock control queries, please contact: sales.sandoz-gb@sandoz.com, Telephone: +44 1276 698607